U.S. FOOD & DRUG ADMINISTRATION

NOTICE OF NONCOMPLIANCE ISSUED PURSUANT TO 42 U.S.C. 282(j)(5)(C)(ii)

VIA UNITED PARCEL SERVICE AND E-MAIL

August 31, 2021

Andrey Petrikovets, M.D.
1513 South Grand Avenue, Suite 400
Los Angeles, California 90015

Re: Notice of Noncompliance with the Requirements for Submission of Clinical Trial Results Information for "ICE-T Postoperative Multimodal Pain Regimen Compared to the Standard Regimen in Same Day Vaginal Pelvic Reconstructive Surgery: A Randomized Controlled Trial" (NCT03052816)
FDA Reference Number: CDER-2020-109

Dear Dr. Petrikovets:

The U.S. Food and Drug Administration (FDA) sent you a letter dated July 20, 2020, alerting you to potential noncompliance with the requirement to submit clinical trial results information to the ClinicalTrials.gov data bank, operated by the National Library of Medicine (a part of the National Institutes of Health), for the above-referenced clinical trial. You are the "responsible party"[1] for the above-referenced clinical trial, which is an "applicable clinical trial"[2] that is subject to the requirements in section 801 of the Food and Drug Administration Amendments Act of 2007 (FDAAA), including its implementing regulations in 42 CFR part 11. A responsible party for an applicable clinical trial is required to submit to the ClinicalTrials.gov data bank certain results information for the clinical trial; such results information generally must be submitted no later than one year after the primary completion date of the applicable clinical trial, unless the responsible party has submitted a certification of delay, a request for an extension of good cause, or a request for a waiver of the requirements for submission of results information.[3]

In our previous letter, we requested that you review your records for this clinical trial and submit all required results information promptly. We also stated that we intended to further review and assess this clinical trial beginning 30 calendar days after you received our previous letter, and that we might take regulatory action if we determined that you were not in compliance at that time.

[1] *See* section 402(j)(1)(A)(ix) of the Public Health Service Act (PHS Act) (42 U.S.C. 282(j)(1)(A)(ix)) and 42 CFR 11.10 for the definition of "responsible party."
[2] *See* section 402(j)(1)(A)(i)-(iii) of the PHS Act (42 U.S.C. 282(j)(1)(A)(i)-(iii)) and 42 CFR 11.10 for the definition of "applicable clinical trial."
[3] *See* section 402(j)(3)(E) of the PHS Act (42 U.S.C. 282(j)(3)(E)) and (H)) and 42 CFR part 11, subpart C for results submission requirements.

We acknowledge receipt of your July 20, 2020, response to our letter including a copy of the published manuscript for the referenced clinical trial. However, as we explained on September 1, 2020, published results in a manuscript are not sufficient to meet the requirements for submission of clinical trial results information to the ClinicalTrials.gov data bank. We also provided you with contact information for the National Library of Medicine's ClinicalTrials.gov contact information for assistance with submitting results information and sent follow-up written communications to you. On November 30, 2020, you responded, stating that you were very busy with the "Covid surge" and were short staffed. Although we recognize the unique circumstances that the pandemic presents, we believe we have provided you ample opportunity to submit the required results information.

FDA has determined that you failed to submit results information for the applicable clinical trial referenced above, as required under section 402(j) of the Public Health Service Act (PHS Act) (42 U.S.C. 282(j)) and 42 CFR 11.48. Pursuant to section 402(j)(5)(C)(ii) of the PHS Act (42 U.S.C. 282(j)(5)(C)(ii)), FDA is notifying you that you are not in compliance with FDAAA's results information submission requirements, which include the requirements in 42 CFR part 11, and that FDA is providing you with the opportunity to remedy your noncompliance by submitting the required clinical trial results information within 30 calendar days after you receive this Notice of Noncompliance (Notice).

Because failure to submit clinical trial information required under section 402(j) of the PHS Act (42 U.S.C. 282(j)) is a prohibited act under section 301(jj)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 331(jj)(2)), FDA may initiate an administrative action seeking a civil monetary penalty against you. Pursuant to section 303(f)(3)(A) of the FD&C Act (21 U.S.C. 333(f)(3)(A)), "[a]ny person who violates section 301(jj) [of the FD&C Act (21 U.S.C. 331(jj))] shall be subject to a civil monetary penalty of not more than $10,000 for all violations adjudicated in a single proceeding."[4]

If you do not submit the required clinical trial results information in the manner and format specified at http://prsinfo.clinicaltrials.gov or at https://clinicaltrials.gov/ct2/manage-recs/how-report within 30 calendar days after receiving this Notice, FDA may also seek additional civil monetary penalties against you. Specifically, section 303(f)(3)(B) of the FD&C Act (21 U.S.C. 333(f)(3)(B)) provides that "[i]f a violation of section 301(jj) [of the FD&C Act (21 U.S.C. 331(jj))] is not corrected within the 30-day period following receipt of a [notice issued] under section 402(j)(5)(C)(ii) [of the PHS Act (42 U.S.C. 282(j)(5)(C)(ii))], the person shall, in addition to any penalty under subparagraph (A), be subject to a civil monetary penalty of not more than $10,000 for each day of the violation after such period until the violation is corrected."

In addition to civil monetary penalties, violations of section 301(jj) of the FD&C Act (21 U.S.C. 331(jj)) could result in other regulatory action, such as injunction and/or criminal prosecution.

[4] The civil monetary penalty amounts in this Notice reflect the amounts listed in the statute. These amounts are updated annually to reflect inflation, as required by the Federal Civil Penalties Inflation Adjustment Act of 1990 (Pub. L. No. 101-410, 104 Stat. 890 (1990) (codified as amended at 28 U.S.C. 2461, note 2(a)), as amended by the Federal Civil Penalties Inflation Adjustment Act Improvements Act of 2015 (Sec. 701 of the Bipartisan Budget Act of 2015, Pub. L. No. 114-74, November 2, 2015). For the most up-to-date amounts, please see 45 CFR 102.3.

If you have any questions about this Notice, you may call David C. Burrow, Pharm.D., J.D., at (301) 796-5632. Please have the FDA reference number provided at the top of this Notice available when you call. Alternatively, you may e-mail Dr. Burrow at CDER-OSI-Advisory@fda.hhs.gov. Please include the FDA reference number with any e-mail communications.

We request that you submit a written response to FDA within 30 calendar days after you receive this Notice, stating the actions you have taken in response to this Notice. Please direct your response to the address below and include the FDA reference number in all correspondence relating to this matter.

David C. Burrow, Pharm.D., J.D.
Director
Office of Scientific Investigations
Office of Compliance
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Building 51, Room 5348
10903 New Hampshire Avenue
Silver Spring, MD 20993

Sincerely yours,

Judith McMeekin, Pharm.D.
Associate Commissioner for Regulatory Affairs
Office of Regulatory Affairs
U.S. Food and Drug Administration